NasdaqGM:LGND

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.


Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Ligand Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LGND's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.05%

LGND

2.0%

US Biotechs

2.3%

US Market


1 Year Return

-6.8%

LGND

27.6%

US Biotechs

6.7%

US Market

Return vs Industry: LGND underperformed the US Biotechs industry which returned 26.3% over the past year.

Return vs Market: LGND underperformed the US Market which returned 6% over the past year.


Shareholder returns

LGNDIndustryMarket
7 Day0.05%2.0%2.3%
30 Day-9.1%7.4%-0.7%
90 Day29.6%25.3%17.1%
1 Year-6.8%-6.8%28.8%27.6%9.0%6.7%
3 Year-4.8%-4.8%34.6%30.2%36.7%27.8%
5 Year8.4%8.4%-3.3%-8.8%65.2%46.9%

Price Volatility Vs. Market

How volatile is Ligand Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ligand Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

2.72x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: LGND ($111.97) is trading above our estimate of fair value ($39.58)

Significantly Below Fair Value: LGND is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: LGND is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: LGND is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LGND's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LGND is good value based on its PB Ratio (2.7x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Ligand Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

92.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LGND is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: LGND is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: LGND's is expected to become profitable in the next 3 years.

Revenue vs Market: LGND's revenue (12.6% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: LGND's revenue (12.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LGND's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Ligand Pharmaceuticals performed over the past 5 years?

38.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LGND is currently unprofitable.

Growing Profit Margin: LGND is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LGND is unprofitable, but has reduced losses over the past 5 years at a rate of 38.1% per year.

Accelerating Growth: Unable to compare LGND's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LGND is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: LGND has a negative Return on Equity (-9.24%), as it is currently unprofitable.


Next Steps

Financial Health

How is Ligand Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: LGND's short term assets ($830.7M) exceed its short term liabilities ($20.4M).

Long Term Liabilities: LGND's short term assets ($830.7M) exceed its long term liabilities ($503.6M).


Debt to Equity History and Analysis

Debt Level: LGND's debt to equity ratio (67.1%) is considered high.

Reducing Debt: LGND's debt to equity ratio has reduced from 598.2% to 67.1% over the past 5 years.

Debt Coverage: LGND's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if LGND's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Ligand Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LGND's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LGND's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LGND's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LGND's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LGND's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

John Higgins (50yo)

13.5yrs

Tenure

US$6,770,376

Compensation

Mr. John L. Higgins has been the Chief Executive Officer at Ligand Pharmaceuticals Incorporated since January 16, 2007. He serves as the President and Chief Executive Officer of Moonstone Acquisition, Inc. ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD6.77M) is above average for companies of similar size in the US market ($USD4.72M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
John Higgins
CEO & Executive Director13.5yrsUS$6.77m1.09% $19.7m
Matthew Foehr
President & COO5.5yrsUS$4.24m0.88% $15.8m
Matthew Korenberg
Executive VP of Finance & CFO4.92yrsUS$3.57m0.16% $2.9m
Charles Berkman
Senior VP13.25yrsUS$2.03m0.26% $4.6m
Patrick O'Brien
Senior Vice President of Investor Relationsno datano datano data
Todd Pettingill
Director of Corporate Developmentno datano datano data
Audrey Warfield-Graham
Senior VP of Human Resources13.5yrsno datano data
Keith Marschke
Senior Vice President of Biology & Scientific Affairs2.5yrsno datano data
Vincent Antle
Senior Vice President of Technical Operations & QA - Capitsol2.5yrsno datano data

5.5yrs

Average Tenure

50yo

Average Age

Experienced Management: LGND's management team is seasoned and experienced (5.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Higgins
CEO & Executive Director13.5yrsUS$6.77m1.09% $19.7m
John Kozarich
Independent Chairman13.33yrsUS$369.90k0.17% $3.0m
Todd Davis
Independent Director13.33yrsUS$349.90k0.31% $5.6m
John LaMattina
Independent Director9.42yrsUS$342.40k0.15% $2.8m
Sunil Patel
Independent Director9.75yrsUS$344.90k0.17% $3.0m
Stephen Sabba
Independent Director11.92yrsUS$359.90k0.15% $2.7m
Jason Aryeh
Independent Director13.83yrsUS$352.40k0.46% $8.2m
Shalendar Bhasin
Scientific Advisorno datano datano data
Sarah Boyce
Independent Director0.75yrUS$457.73k0.014% $253.2k
Nancy Gray
Independent Director2.92yrsUS$344.90k0.019% $344.0k

11.9yrs

Average Tenure

59yo

Average Age

Experienced Board: LGND's board of directors are seasoned and experienced ( 11.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: LGND insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ligand Pharmaceuticals Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ligand Pharmaceuticals Incorporated
  • Ticker: LGND
  • Exchange: NasdaqGM
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.797b
  • Shares outstanding: 16.05m
  • Website: https://www.ligand.com

Number of Employees


Location

  • Ligand Pharmaceuticals Incorporated
  • 3911 Sorrento Valley Boulevard
  • Suite 110
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LGNDNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 1994
LGDNDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1994

Biography

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company’s partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/08 23:56
End of Day Share Price2020/07/08 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.